Intramuscular Use: Injectable corticosteroids like Triamcinolone are indicated when oral therapy is not feasible. They are used for short-term adjunctive therapy to manage acute episodes or exacerbations in the following conditions:

• Rheumatic disorders: Acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis).
• Allergic states: Severe or incapacitating asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
• Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
• Endocrine disorders: Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
• Gastrointestinal diseases: Regional enteritis, ulcerative colitis.
• Hematologic disorders: Autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected secondary thrombocytopenia.
• Neoplastic diseases: Palliative management of leukemias and lymphomas.
• Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema due to primary/metastatic brain tumor or craniotomy.
• Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids.
• Renal diseases: Idiopathic nephrotic syndrome or lupus nephritis to induce diuresis or reduce proteinuria.
• Respiratory diseases: Berylliosis, fulminant or disseminated pulmonary tuberculosis (with antitubercular therapy), idiopathic eosinophilic pneumonia, symptomatic sarcoidosis.
• Miscellaneous: Trichinosis with neurological/myocardial involvement, tuberculous meningitis (with subarachnoid block, with antitubercular therapy).

Intra-articular/Local Use: Triamcinolone injection may be used for short-term relief in acute gouty arthritis, bursitis, tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.

Appearance: White to cream-colored crystalline powder, slightly odorous, insoluble in water, soluble in alcohol.

Action: Synthetic glucocorticoid with anti-inflammatory properties, suitable for intramuscular and intra-articular use only.

Absorption & Duration: After a single IM dose (60–100 mg), adrenal suppression occurs within 24–48 hours, returning to normal in 30–40 days. Effects can last several weeks.

General

• Dosage: The initial dose of Triamcinolone injection may vary from 2.5 mg to 100 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified. Dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.
• Administration: Strict aseptic technique is mandatory. The vial should be shaken before use to ensure a uniform suspension. Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).

Systemic

• Dosage: The suggested initial dose is 60 mg, injected deeply into the gluteal muscle. Atrophy of subcutaneous fat may occur if the injection is not properly given. Dosage is usually adjusted within the range of 40 mg to 80 mg, depending upon patient response and duration of relief. However, some patients may be well controlled on doses as low as 20 mg or less. Pediatric patients: The range of initial doses is 0.11 to 1.6 mg/kg/day in 3 or 4 divided doses.
• Administration: For systemic therapy, injection should be made deeply into the gluteal muscle. For adults, a minimum needle length of 11/2 inches is recommended. In obese patients, a longer needle may be required. Use alternative sites for subsequent injections.

Local

• Dosage: Intra-articular administration: A single local injection of Triamcinolone Acetonide is frequently sufficient, but several injections may be needed for adequate relief of symptoms. Initial dose: 2.5 mg to 5 mg for smaller joints and from 5 mg to 15 mg for larger joints, depending on the specific disease entity being treated. For adults, doses up to 10 mg for smaller areas and up to 40 mg for larger areas have usually been sufficient. Single injections into several joints, up to a total of 80 mg, have been given.
• Administration: For treatment of joints, the usual intra-articular injection technique should be followed. If an excessive amount of synovial fluid is present in the joint, some, but not all, should be aspirated to aid in the relief of pain and to prevent undue dilution of the steroid.

Aminoglutethimide: May reduce steroid effect.

Amphotericin B & potassium-depleting agents: Monitor for hypokalemia.

Antibiotics (macrolides), anticholinesterases, anticoagulants, antidiabetics, antitubercular drugs, cholestyramine, cyclosporine, digitalis, estrogens, hepatic enzyme inducers, ketoconazole, NSAIDs: Various interactions affecting steroid metabolism, efficacy, or side effects.

Vaccines/Skin tests: Corticosteroids may suppress responses.

Hypersensitivity to any component. Intramuscular corticosteroids are contraindicated in idiopathic thrombocytopenic purpura.

• Allergic: Anaphylaxis, angioedema.
• Cardiovascular: Hypertension, arrhythmias, heart failure, embolism.
• Dermatologic: Acne, skin atrophy, rash, purpura, striae, thin skin.
• Endocrine: Cushingoid effects, hyperglycemia, growth suppression (pediatric).
• Fluid/Electrolytes: Edema, hypokalemia.
• GI: Nausea, ulcers, pancreatitis.
• Musculoskeletal: Osteoporosis, myopathy, tendon rupture, fractures.
• Neurologic/Psychiatric: Mood changes, insomnia, depression, seizures.
• Ophthalmic: Glaucoma, cataracts, elevated intraocular pressure.

Category C: Use only if benefits outweigh risks. Corticosteroids appear in breast milk; caution in nursing women.

• Use lowest effective dose; taper gradually if possible.
• Monitor in patients with heart failure, hypertension, renal impairment, or peptic ulcers.
• Monitor intraocular pressure if treatment exceeds 6 weeks.
• Prolonged therapy requires periodic evaluation for adrenal suppression.

Pediatric: Higher susceptibility to side effects; limit dose.

Geriatric: No significant differences, but some older individuals may be more sensitive.

Acute: Supportive and symptomatic treatment.

Chronic: Reduce dose temporarily or use alternate-day therapy.

Corticosteroid, Glucocorticoid, Triamcinolone & combined preparations.

Store at 20–25°C, avoid freezing and light exposure.